Details of the Drug

General Information of Drug (ID: DMS3GVE)

• Drug Name: Desmopressin
• Synonyms: Ddavp; DESMOPRESSIN; DDAVP; dAVP; Minirin; Adiuretin SD; Noctiva; Adiuretin; Deamino Arginine Vasopressin; Desmopressinum; deamino-vasopressin; [deamino1]AVP; Desmopressin [INN:BAN]; [deamino-Cys1]AVP; Desmopressinum [INN-Latin]; Desmopressine [INN-French]; Desmopresina [INN-Spanish]; Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-; desnopressin; Vasopressin, Deamino Arginine; EINECS 240-726-7; 1-Desamino-8-D-arginine vasopressin; Desamino-8-D-arginine vasopressin, l-; Deamino-8-D-arginine, l-, vasopressin; Desmopressin Melt; Minrin Melt; FE-992026; Desmopressin (fast-dissolving, nocturia/diabetes insipidus); Desmopressin (fast-dissolving, nocturia/diabetes insipidus), Ferring Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1]
Haemophilia A	3B10.0	Approved	[2]
Nocturia	MF55	Approved	[2]
Von willebrand disease	3B12	Approved	[2]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 5:
  Molecular Weight (mw); 1069.2
  Logarithm of the Partition Coefficient (xlogp); -4
  Rotatable Bond Count (rotbonds); 19
  Hydrogen Bond Donor Count (hbonddonor); 13
  Hydrogen Bond Acceptor Count (hbondacc); 15
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
  Bioavailability: The bioavailability of drug is 90-100% [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 1.4 mL/min/kg [5]
  Elimination: About 65% of oral dose is recovered in the urine within 24 hours [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2.8 hours [6]
  Metabolism: The drug is metabolized via the liver [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0000254 micromolar/kg/day [7]
  Vd: The volume of distribution (Vd) of drug is 0.2-0.32 L/kg [6]
• Chemical Identifiers:
  Formula: C46H64N14O12S2
  IUPAC Name: (2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
  Canonical SMILES: C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N
  InChI: InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1
  InChIKey: NFLWUMRGJYTJIN-PNIOQBSNSA-N
• Cross-matching ID:
  PubChem CID: 5311065
  ChEBI ID: CHEBI:4450
  CAS Number: 16679-58-6
  DrugBank ID: DB00035
  TTD ID: D0U7SH
  VARIDT ID: DR01209
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxytocin receptor (OTR)	TTSCIUP	OXYR_HUMAN	Agonist	[8]
Vasopressin receptor (VR)	TTYCILE	NOUNIPROTAC	Modulator	[9]
Vasopressin V1a receptor (V1AR)	TT4TFGN	V1AR_HUMAN	Agonist	[8]
Vasopressin V1b receptor (V1BR)	TTL9MHW	V1BR_HUMAN	Agonist	[8]
Vasopressin V2 receptor (V2R)	TTK8R02	V2R_HUMAN	Agonist	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cystic fibrosis transmembrane conductance regulator (CFTR)	OT6B22QH	CFTR_HUMAN	Gene/Protein Processing	[10]
von Willebrand factor	OTNMMA2P	VWF_HUMAN	Gene/Protein Processing	[11]

Molecular Expression Atlas of This Drug

• The Studied Disease: Diabetic complication
• ICD Disease Classification: 5A2Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Vasopressin V1b receptor (V1BR)	DTT	AVPR1B	5.14E-01	-0.03	-0.15

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Desmopressin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Oliceridine.	Acute pain [MG31]	[12]
Budesonide	DMJIBAW	Major	Increased risk of hyponatremia by the combination of Desmopressin and Budesonide.	Asthma [CA23]	[13]
Desipramine	DMT2FDC	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[14]
Lamotrigine	DM8SXYG	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Lamotrigine.	Bipolar disorder [6A60]	[14]
Loperamide	DMOJZQ9	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Loperamide.	Bowel habit change [ME05]	[12]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Phenylbutazone.	Chronic pain [MG30]	[15]
Dihydrocodeine	DMB0FWL	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Dihydrocodeine.	Chronic pain [MG30]	[16]
Ketoprofen	DMRKXPT	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Ketoprofen.	Chronic pain [MG30]	[14]
Morphine	DMRMS0L	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Morphine.	Chronic pain [MG30]	[12]
Levomilnacipran	DMV26S8	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Levomilnacipran.	Chronic pain [MG30]	[14]
Alfentanil	DMVO0UB	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Alfentanil.	Corneal disease [9A76-9A78]	[12]
Remifentanil	DMZTXCH	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Remifentanil.	Corneal disease [9A76-9A78]	[12]
Methadone	DMTW6IU	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Methadone.	Cough [MD12]	[12]
Sertraline	DM0FB1J	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Sertraline.	Depression [6A70-6A7Z]	[14]
Trimipramine	DM1SC8M	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Trimipramine.	Depression [6A70-6A7Z]	[14]
Imipramine	DM2NUH3	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Imipramine.	Depression [6A70-6A7Z]	[14]
Fluoxetine	DM3PD2C	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Fluoxetine.	Depression [6A70-6A7Z]	[14]
Nortriptyline	DM4KDYJ	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Nortriptyline.	Depression [6A70-6A7Z]	[14]
Vilazodone	DM4LECQ	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Vilazodone.	Depression [6A70-6A7Z]	[14]
Paroxetine	DM5PVQE	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Paroxetine.	Depression [6A70-6A7Z]	[14]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Vortioxetine.	Depression [6A70-6A7Z]	[14]
Duloxetine	DM9BI7M	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Duloxetine.	Depression [6A70-6A7Z]	[14]
Milnacipran	DMBFE74	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Milnacipran.	Depression [6A70-6A7Z]	[14]
Escitalopram	DMFK9HG	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Escitalopram.	Depression [6A70-6A7Z]	[14]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Desvenlafaxine.	Depression [6A70-6A7Z]	[14]
Clomipramine	DMINRKW	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Clomipramine.	Depression [6A70-6A7Z]	[14]
Amitriptyline	DMK7F9S	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Amitriptyline.	Depression [6A70-6A7Z]	[14]
Amoxapine	DMKITQE	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Amoxapine.	Depression [6A70-6A7Z]	[14]
Mirtazapine	DML53ZJ	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Mirtazapine.	Depression [6A70-6A7Z]	[14]
Protriptyline	DMNHTZI	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Protriptyline.	Depression [6A70-6A7Z]	[14]
Doxepin	DMPI98T	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Doxepin.	Depression [6A70-6A7Z]	[14]
Maprotiline	DMPWB7T	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Maprotiline.	Depression [6A70-6A7Z]	[14]
Fluvoxamine	DMQTJSX	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Fluvoxamine.	Depression [6A70-6A7Z]	[14]
Venlafaxine	DMR6QH0	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Venlafaxine.	Depression [6A70-6A7Z]	[14]
Citalopram derivative 1	DMITX1G	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Citalopram derivative 1.	Discovery agent [N.A.]	[14]
Felbamate	DM1V5ZS	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Felbamate.	Epilepsy/seizure [8A61-8A6Z]	[14]
Oxcarbazepine	DM5PU6O	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Oxcarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[14]
Carbamazepine	DMZOLBI	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[14]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[14]
Ethacrynic acid	DM60QMR	Major	Increased risk of hyponatremia by the combination of Desmopressin and Ethacrynic acid.	Essential hypertension [BA00]	[17]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Mefenamic acid.	Female pelvic pain [GA34]	[14]
Furosemide	DMMQ8ZG	Major	Increased risk of hyponatremia by the combination of Desmopressin and Furosemide.	Heart failure [BD10-BD1Z]	[13]
Bumetanide	DMRV7H0	Major	Increased risk of hyponatremia by the combination of Desmopressin and Bumetanide.	Heart failure [BD10-BD1Z]	[13]
Torasemide	DMXKJ6C	Major	Increased risk of hyponatremia by the combination of Desmopressin and Torasemide.	Heart failure [BD10-BD1Z]	[17]
Clofibrate	DMPC1J7	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Clofibrate.	Hyper-lipoproteinaemia [5C80]	[14]
Methyldopa	DM5I621	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Methyldopa.	Hypertension [BA00-BA04]	[14]
Enalapril	DMNFUZR	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Enalapril.	Hypertension [BA00-BA04]	[14]
Fludrocortisone	DMUDIR8	Major	Increased risk of hyponatremia by the combination of Desmopressin and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[13]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[18]
Vincristine	DMINOX3	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Vincristine.	Mature B-cell lymphoma [2A85]	[14]
Deflazacort	DMV0RNS	Major	Increased risk of hyponatremia by the combination of Desmopressin and Deflazacort.	Muscular dystrophy [8C70]	[13]
Urea	DMUK75B	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Urea.	Oesophagitis [DA24]	[14]
Levomethadyl Acetate	DM06HG5	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[16]
Rofecoxib	DM3P5DA	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Rofecoxib.	Osteoarthritis [FA00-FA05]	[14]
Valdecoxib	DMAY7H4	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Valdecoxib.	Osteoarthritis [FA00-FA05]	[14]
Diclofenac	DMPIHLS	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Diclofenac.	Osteoarthritis [FA00-FA05]	[14]
Naproxen	DMZ5RGV	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Naproxen.	Osteoarthritis [FA00-FA05]	[14]
Pentazocine	DM1XBHS	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Pentazocine.	Pain [MG30-MG3Z]	[12]
Dextropropoxyphene	DM23HCX	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Dextropropoxyphene.	Pain [MG30-MG3Z]	[16]
Butorphanol	DM5KYPJ	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Butorphanol.	Pain [MG30-MG3Z]	[12]
Oxymorphone	DM65AGJ	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Oxymorphone.	Pain [MG30-MG3Z]	[12]
Etodolac	DM6WJO9	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Etodolac.	Pain [MG30-MG3Z]	[14]
Ibuprofen	DM8VCBE	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Ibuprofen.	Pain [MG30-MG3Z]	[14]
Nabumetone	DMAT2XH	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Nabumetone.	Pain [MG30-MG3Z]	[14]
Levorphanol	DMGS80V	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Levorphanol.	Pain [MG30-MG3Z]	[12]
Hydromorphone	DMHP21E	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Hydromorphone.	Pain [MG30-MG3Z]	[12]
Dezocine	DMJDB0Y	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Dezocine.	Pain [MG30-MG3Z]	[12]
Codeine	DMJX6ZG	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Codeine.	Pain [MG30-MG3Z]	[12]
Nalbuphine	DMOSQGU	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Nalbuphine.	Pain [MG30-MG3Z]	[12]
Buprenorphine	DMPRI8G	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Buprenorphine.	Pain [MG30-MG3Z]	[12]
Hydrocodone	DMQ2JO5	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Hydrocodone.	Pain [MG30-MG3Z]	[12]
Tramadol	DMRQD04	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Tramadol.	Pain [MG30-MG3Z]	[12]
Piroxicam	DMTK234	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Piroxicam.	Pain [MG30-MG3Z]	[14]
Meperidine	DMX4GND	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Meperidine.	Pain [MG30-MG3Z]	[12]
Oxycodone	DMXLKHV	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Oxycodone.	Pain [MG30-MG3Z]	[12]
Prednisone	DM2HG4X	Major	Increased risk of hyponatremia by the combination of Desmopressin and Prednisone.	Postoperative inflammation [1A00-CA43]	[13]
Betamethasone	DMAHJEF	Major	Increased risk of hyponatremia by the combination of Desmopressin and Betamethasone.	Postoperative inflammation [1A00-CA43]	[13]
Hydrocortisone	DMGEMB7	Major	Increased risk of hyponatremia by the combination of Desmopressin and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[13]
Ketorolac	DMI4EL5	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Ketorolac.	Postoperative inflammation [1A00-CA43]	[14]
Bromfenac	DMKB79O	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Bromfenac.	Postoperative inflammation [1A00-CA43]	[14]
Ciclesonide	DM2NA4K	Major	Increased risk of hyponatremia by the combination of Desmopressin and Ciclesonide.	Respiratory system disease [CB40-CB7Z]	[13]
Meloxicam	DM2AR7L	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Meloxicam.	Rheumatoid arthritis [FA20]	[14]
Sulindac	DM2QHZU	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Sulindac.	Rheumatoid arthritis [FA20]	[14]
Celecoxib	DM6LOQU	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Celecoxib.	Rheumatoid arthritis [FA20]	[14]
Oxaprozin	DM9UB0P	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Oxaprozin.	Rheumatoid arthritis [FA20]	[14]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Flurbiprofen.	Rheumatoid arthritis [FA20]	[14]
Fenoprofen	DML5VQ0	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Fenoprofen.	Rheumatoid arthritis [FA20]	[14]
Dexamethasone	DMMWZET	Major	Increased risk of hyponatremia by the combination of Desmopressin and Dexamethasone.	Rheumatoid arthritis [FA20]	[13]
Indomethacin	DMSC4A7	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Indomethacin.	Rheumatoid arthritis [FA20]	[14]
Tolmetin	DMWUIJE	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Tolmetin.	Rheumatoid arthritis [FA20]	[14]
Haloperidol	DM96SE0	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Haloperidol.	Schizophrenia [6A20]	[14]
Chlorpromazine	DMBGZI3	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Chlorpromazine.	Schizophrenia [6A20]	[14]
Fentanyl	DM8WAHT	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Fentanyl.	Sensation disturbance [MB40]	[12]
Sufentanil	DMU7YEL	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Sufentanil.	Sensation disturbance [MB40]	[12]
Methylprednisolone	DM4BDON	Major	Increased risk of hyponatremia by the combination of Desmopressin and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[13]
Cyclophosphamide	DM4O2Z7	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Cyclophosphamide.	Solid tumour/cancer [2A00-2F9Z]	[14]
Vinblastine	DM5TVS3	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Vinblastine.	Solid tumour/cancer [2A00-2F9Z]	[14]
Ifosfamide	DMCT3I8	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[14]
Prednisolone	DMQ8FR2	Major	Increased risk of hyponatremia by the combination of Desmopressin and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[13]
Cisplatin	DMRHGI9	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[14]
Vinorelbine	DMVXFYE	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Vinorelbine.	Solid tumour/cancer [2A00-2F9Z]	[14]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hyponatremia by the combination of Desmopressin and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[14]
Triamcinolone	DM98IXF	Major	Increased risk of hyponatremia by the combination of Desmopressin and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[13]
Fluticasone	DMGCSVF	Major	Increased risk of hyponatremia by the combination of Desmopressin and Fluticasone.	Vasomotor/allergic rhinitis [CA08]	[13]
Flunisolide	DMZSWQC	Major	Increased risk of hyponatremia by the combination of Desmopressin and Flunisolide.	Vasomotor/allergic rhinitis [CA08]	[13]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2182).
• [2] Desmopressin FDA Label
• [3] FDA Approved Drug Products: RAZADYNE (galantamine hydrobromide), for oral use
• [4] BDDCS applied to over 900 drugs
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] UKPAR for Desmopressin acetate 100mcg and 200mcg Tablets
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
• [9] Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90.
• [10] Vasotocin and vasopressin stimulation of the chloride secretion in the human bronchial epithelial cell line, 16HBE14o-. Br J Pharmacol. 2005 Apr;144(8):1037-50. doi: 10.1038/sj.bjp.0706103.
• [11] Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. J Lab Clin Med. 1989 Jul;114(1):36-42.
• [12] Sarret D, Le Berre JP, Zemraoui N "Tramadol-induced hyponatremia." Am J Kidney Dis 52 (2008): 1026 author reply 1027. [PMID: 18971023]
• [13] Product Information. Stimate (desmopressin). Forest Pharmaceuticals, St. Louis, MO.
• [14] Cerner Multum, Inc. "Australian Product Information.".
• [15] Vanhees SL, Paridaens R, Vansteenkiste JF "Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review." Ann Oncol 11 (2000): 1061-5. [PMID: 11038047]
• [16] Appel WC "Possible roles of normeperidine and hyponatremia in a postoperative death." Can Med Assoc J 137 (1987): 912-3. [PMID: 3676934]
• [17] Product Information. Nocdurna (desmopressin). Ferring Inc, North York, ON.
• [18] Kosmidis HV, Bouhoutsou DO, Varvoutsi MC, et al. "Vincristine overdose: experience with 3 patients." Pediatr Hematol Oncol 8 (1991): 171-8. [PMID: 1863543]